This question usually arrives with a story attached. The symptoms started years ago, but they were called stress, or depression, or just life. The penny dropped late, sometimes a decade late, and now every article mentions a window and the arithmetic feels unforgiving.
Here is the honest position: the window is real, it is about where the evidence is strongest rather than a door that slams, and the conversation at 58 or 62 is different from the one at 48 rather than closed. This guide explains what actually changes with time, because understanding that is what makes the late conversation a good one.
What the window actually is
The phrase you will meet is the timing hypothesis. In the big reanalyses of the hormone therapy trials, women who started under 60, or within ten years of their final period, showed the most favourable balance of benefits and risks, including for their hearts. Women starting well beyond that point showed a less favourable picture, particularly with tablet forms.
That is what the window means. It is a description of where the reassuring evidence is concentrated, not a biological cliff on your sixtieth birthday. The menopause societies on both sides of the Atlantic are explicit that starting later can still be reasonable; it simply calls for a more individual assessment.
What changes in the conversation after the window
Three things, mainly. First, the cardiovascular question inverts: inside the window estrogen looks neutral to protective for the heart; started long after, it may add risk in ways that depend on the state of your arteries. So the late conversation includes your blood pressure, lipids and any cardiac history in a way the early one might not.
Second, the reason for starting gets weighed more carefully. Flashes and sweats that are still troublesome at 62 remain a solid reason, and about a quarter of women do still have them a decade past their last period. Bone protection remains real at any starting age. Vaguer hopes, sharper scrutiny.
Third, the route matters more. Through the skin rather than tablets becomes close to a default in later starts, because it sidesteps the clot question. Low starting doses, gradual reviews. None of this is dramatic; it is just careful medicine.
The part that has no window at all
Vaginal estrogen sits outside this entire discussion. Dryness, discomfort and urinary changes affect more than half of women after menopause, tend to worsen rather than pass, and respond well to local treatment that barely reaches the rest of the body. The professional societies are comfortable with it at any age, and with continuing indefinitely.
It is also the most under-asked-for treatment in the whole field, because the symptoms are the ones women mention least. If this paragraph is describing your situation, that alone is worth an appointment, at any age, window or no window.
If you are deciding late, decide well
A late start is a specialist-flavoured conversation, so aim it at someone with menopause credentials rather than whoever has the first free slot. Bring the actual timeline: your last period if you know it, when each symptom started, what you have tried. The free report on this site turns that into one page.
And hold both honest truths at once. Starting at 61 is not what the strongest evidence describes, and it is done, thoughtfully, for women whose symptoms or bones justify it. The wrong conclusions are the two easy ones: that it is fine for everyone, or that it is forbidden for you. The right one takes one appointment to reach.
Common questions
I am 57 and my last period was six years ago. Am I inside the window?
By both common definitions, yes: under 60 and within ten years of the final period. Your conversation is still the standard one, covering your own history and what you are treating, but the timing question itself is not a barrier at all here.
Is there an age where HRT must be stopped?
No. Guidance on both sides of the Atlantic supports continuing for as long as benefits outweigh risks for you, with a proper review each year. Plenty of women continue into their late 60s and beyond, particularly on transdermal forms and lower doses.
I never had flashes, but my bones are thinning. Is HRT still relevant?
Bone protection is one of HRT's best-evidenced effects, and it is a legitimate primary reason to consider it, particularly for women with early menopause or osteoporosis risk. That conversation sits alongside the other bone options, and a DEXA scan usually anchors it.
Sources
- The Menopause Society, 2022 hormone therapy position statement
- British Menopause Society, HRT in older women guidance
- The Menopause Society clinical guidance; NICE guideline NG23 (UK)
- Women's Health Initiative long-term follow-up publications
- Royal Osteoporosis Society guidance
General information, not medical advice. Narrated never diagnoses.